Tobetsa mona ho bonts'a lifolakha tsa HAO leqepheng lena mme u lefelle katleho feela

Litaba tsa mohala

Bakuli ba Lebrikizumab ba Finyella Tlhokomelo ea Letlalo ho tsoa ho monotherapy

ngotsoeng ke mohlophisi

Ho feta karolo ea 50 lekholong ea bakuli ba nang le "atopic dermatitis" e leka-lekaneng ho isa ho e matla (AD) ba bile le phokotso ea liperesente tse 75 ho matla a lefu (EASI-75*) libekeng tse 16 ha ba amohela lebrikizumab monotherapy lenaneong la Advocate, Eli Lilly and Company (NYSE). : LLY) e phatlalalitse kajeno Sebokeng sa Selemo le Selemo sa American Academy of Dermatology (AAD). Lebrikizumab, e leng IL-13 inhibitor ea lipatlisiso, le eona e lebisitse ntlafatsong e nang le morero ho itch le liphetho tse ling tsa bohlokoa tse tlalehiloeng ke bakuli ha li bapisoa le placebo.

Emma Guttman-Yassky, MD, Ph.D., moprofesa oa Waldman o itse: "Bakuli ba nang le atopic dermatitis ba na le ho hlohlona ho sa khaotseng, letlalo le omeletseng, bohloko bo tebileng le ho ruruha, tse ka 'nang tsa e-ba tse sa lebelloang' me tsa ama mosebetsi oa bona, likamano tsa sechaba, bophelo bo botle ba kelello le maikutlo. le molula-setulo oa tsamaiso ea Dermatology Sekolong sa Bongaka sa Icahn se Mount Sinai New York, le mongoli e moholo oa Advocate o hlahloba. "Lebrikizumab ke kalafo e ncha e shebaneng le tsela ea IL-13, e leng eona mokhanni oa mantlha oa cytokine ea ho ruruha e amehang ho AD. Ke khothatsoa ke lintlha tsa kajeno tse bonts'ang lintlafatso tse potlakileng letlalong, ho hlohlona le mehato ea boleng ba bophelo. ”

Lebrikizumab ke monoclonal antibody (mAb) e tlamang protheine ea interleukin 13 (IL-13) e nang le kamano e phahameng ho thibela ka ho khetheha ho thehoa ha IL-13Rα1 / IL-4Rα (Mofuta oa 2 receptor) e thibelang pontšo e tlaase ka IL-13. tsela. 1-5 IL-13 e bapala karolo e ka sehloohong ho ho ruruha ha Mofuta oa 2. Ka AD, IL-6 e fana ka matšoao le matšoao a kenyeletsang ho se sebetse ha mokoallo oa letlalo, ho hlohlona, ​​tšoaetso le libaka tse thata, tse teteaneng tsa letlalo.13

Ho 'Muelli oa 1, karolo ea 43 lekholong ea bakuli ba fumanang lebrikizumab e fihletse letlalo le hlakileng kapa le batlang le hlakile (IGA) libeke tse 16 ha li bapisoa le liperesente tse 13 tsa bakuli ba nkang placebo. Har'a ba fumanang lebrikizumab, karolo ea 59 lekholong e fumane karabo ea EASI-75, ha e bapisoa le karolo ea 16 lekholong e nang le placebo.

Ho 'Muelli oa 2, karolo ea 33 lekholong ea bakuli ba nkang lebrikizumab ba fihletse letlalo le hlakileng kapa le batlang le hlakile (IGA) libeke tse 16, ha li bapisoa le liperesente tse 11 tsa bakuli ba placebo. Har'a ba fumanang lebrikizumab, karolo ea 51 lekholong e fumane karabo ea EASI-75, ha e bapisoa le karolo ea 18 lekholong e nkang placebo.

Nakong ea libeke tse 'nè, bakuli ba fumanang lebrikizumab ba ile ba fumana ntlafatso e kholo ea lipalo-palo tabeng ea ho hloekisoa ha letlalo le ho hlohlona, ​​hammoho le ntlafatso ea ho kena-kenana le ho hlohlona ha boroko, le boleng ba bophelo, joalokaha ho lekantsoe ke lintlha tsa bohlokoa tsa bobeli.

Boemo ba polokeho ea nako ea libeke tse 16 bo ne bo lumellana le lithuto tsa pele tsa lebrikizumab ho AD. Bakuli ba nkang lebrikizumab, ha ba bapisoa le placebo, ba tlalehile makhetlo a fokolang a liketsahalo tse mpe ho ADvocate 1 (lebrikizumab: 45%, placebo: 52%) le Advocate 2 (lebrikizumab: 53%, placebo: 66%). Liketsahalo tse mpe ka ho fetisisa ho pholletsa le lithuto tse peli li ne li le bonolo kapa li itekanetse ka matla le tse se nang letho 'me ha lia ka tsa lebisa ho khaotsoe ke phekolo. Liketsahalo tse mpe tse atileng haholo ho Advocate 1 le 2 bakeng sa ba lebrikizumab e ne e le conjunctivitis (7% le 8%, ka ho latellana), sefuba se tloaelehileng (nasopharyngitis) (4% le 5%, ka ho latellana) le hlooho (3% le 5%, ka ho latellana). ).

"Liphihlelo tsa batho le ho loana le mafu a autoimmune, joalo ka atopic dermatitis, li re khannela Lilly ho phehella saense e ncha le liphekolo tse nang le morero tse ntlafatsang bophelo, haholo libakeng tseo ho nang le tlhoko e potlakileng," ho boletse Lotus Mallbris, MD, Ph.D. ., motlatsi oa mopresidente oa nts'etsopele ea lefats'e ea immunology le litaba tsa bongaka Lilly. "Lintlha tsena li tiisa liphello tse ntle lenaneong la rona la ntlafatso la Mokhahlelo oa 3, 'me re lumela hore lebrikizumab e emela moloko o mocha oa biologics bakeng sa AD."

Liphetho tse felletseng tsa libeke tse 52 ho tsoa ho Advocate 1 le 2, hammoho le data ea libeke tse 16 ho tsoa ho ADhere, thuto ea Phase 3 AD ea lebrikizumab e nang le li-topical steroids, e tla senoloa likhoeling tse tlang. Lilly le Almirall SA ba rera ho romela lifaele ho balaoli ba tsamaiso lefats'eng ka bophara bofelong ba 2022 kamora ho phethoa ha lithuto tsa Akhente.

"Bakuli ba hloka mekhoa e mecha ea phekolo e fanang ka katleho e phahameng le mamello. Lintlha tsena tse ntle li bontša hore lebrikizumab e na le monyetla oa ho ba pheko e ka sehloohong AD,” ho boletse Karl Ziegelbauer, Ph.D., Ofisiri e ka Sehloohong ea Saense ea Almirall.

Lilly o na le litokelo tse khethehileng bakeng sa nts'etsopele le khoebo ea lebrikizumab United States le lefats'eng lohle ka ntle ho Europe. Almirall e fane ka tumello ea ho hlahisa le ho rekisa lebrikizumab bakeng sa kalafo ea matšoao a letlalo, ho kenyeletsoa AD, Europe.

Litaba Tse Amanang

Mabapi le mongoli

mohlophisi

Mohlophisi e moholo oa eTurboNew ke Linda Hohnholz. O lula ntlong e kholo ea eTN e Honolulu, Hawaii.

Leave a Comment

Arolelana ho...